Regeneron Pharmaceuticals authorizes $3B for stock buybacks

How big is it?

Regeneron Pharmaceuticals bought back $3.3B of stock in the twelve months to Jun 30, 2026. At that pace, $3.0B covers about 11 months of buybacks.

The amount equals 80% of its free cash flow over the same twelve months ($3.8B).

Its diluted share count is down 2.4% from a year earlier.

An authorization is permission, not a promise: the company can buy less, more slowly, or not at all, and usually doesn't have to say when it buys.

Full Regeneron Pharmaceuticals buyback record →